Stock Track | Alvotech Plummets 9.52% Intraday Following Q1 Earnings Miss and Revenue Decline

Stock Track05-07

Alvotech's stock plummeted 9.52% during intraday trading on Thursday, extending losses from earlier sessions.

The sharp decline follows the biotechnology company's disappointing first-quarter 2026 financial results, which showed revenue of $105.9 million - a 20.3% decrease from the same period last year and significantly below analyst estimates of $140.85 million. The company also reported breakeven earnings per share, missing expectations of 2 cents per share.

CEO Lisa Graver attributed the weaker performance to a production slowdown related to facility improvements, which impacted both revenues and EBITDA. While the company maintained its full-year revenue guidance of $650-$700 million and adjusted EBITDA guidance of $180-$220 million, investors reacted negatively to the quarterly miss.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment